معرفی
George Follows serves as Visiting Professor of Haematology at Anglia Ruskin University and Associate Professor of Haematology at the University of Cambridge. He leads haematology clinical trials at the Cambridge Cancer Trials Centre and chairs the UK Hodgkin Lymphoma Guidelines Panel, following prior leadership roles in CLL research and guidelines development.
His educational background includes a medical degree from Oxford University Medical School, PhD from Leeds University, and qualifications: BM, BCh and MA (Oxford); PhD (Leeds); FRCP and FRCPath (London). Professional memberships include Fellow of the Royal College of Physicians, Fellow of the Royal College of Pathologists, and British Haematology Society.
Professor Follows specializes in haematological malignancies with emphasis on lymphoma, chronic lymphocytic leukemia (CLL), and Hodgkin Lymphoma. His research integrates clinical trial leadership with guideline development, focusing on targeted therapies and translational applications. Current work addresses minimal residual disease detection, novel drug combinations, and palliative approaches for refractory cases.
Recent publications reveal strong trends in CLL therapeutics (ibrutinib/venetoclax combinations) and Hodgkin Lymphoma management guidelines. Research spans clinical trial design for regulatory approvals, real-world lymphoma treatment challenges, and post-transplant complications, consistently targeting therapeutic optimization.
No scientific awards are documented in the provided materials.
He maintains extensive industry collaborations with pharmaceutical and biotechnology partners, securing funding for clinical trials that generated over 100 publications in premier journals. While specific advisees aren't listed, his leadership in trial design and guideline panels demonstrates significant academic influence.
Professor Follows directs research teams at the Cambridge Cancer Trials Centre, coordinating multicentre clinical trials across UK transplant centres and lymphoma networks, with active participation in international therapeutic development consortia.
